Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
针对复发/难治性慢性淋巴细胞白血病的响应适应性、限时维奈托克、乌布拉利西布和乌布妥昔单抗治疗
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2023010693
Hill, Brian T; Ma, Shuo; Zent, Clive S; Baran, Andrea M; Wallace, Danielle S; Advani, Anjali; Winter, Allison; Winter, Jane; Gordan, Leo; Karmali, Reem; Liesveld, Jane L; Mulford, Deborah A; Rowland, Chris; Bui, Andrew; Sportelli, Peter; Miskin, Hari P; Weiss, Michael S; Friedberg, Jonathan W; Barr, Paul M